The combined analysis of LUX-Lung 3 and 6 trials, afatinib, a second-generation EGFR TKI significantly improved progression-free survival in patients with NSCLC plus brain metastases and common EGFR mutations (8.2 vs. 5.4 months; hazard ratio, 0.50)20. This evidence concerns the gene EGFR and non-small cell lung carcinoma.